Met in urological cancers.
作者： Yasuyoshi Miyata , Akihiro Asai , Kensuke Mitsunari , Tomohiro Matsuo , Kojiro Ohba
关键词: Oncology 、 Metastasis 、 Prostate cancer 、 Clinical significance 、 Receptor tyrosine kinase 、 Clinical trial 、 Internal medicine 、 Pathology 、 Medicine 、 Pathological 、 Renal cell carcinoma 、 Cancer
摘要: Met is a tyrosine kinase receptor that considered to be proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis many types of malignancies. Furthermore, expression has been reported useful predictive biomarker for disease progression patient survival these Many studies have focused on the clinical significance prognostic urological cancers, including prostate cancer (PCa), renal cell carcinoma (RCC), urothelial cancer. Several preclinical trials are progress. In this review, current understanding pathological lines, its tissues, value patients with cancers summarized. particular, Met-related malignant behavior castration-resistant PCa different roles papillary RCC other histological subjects focus. addition, phosphorylated shown. recent years, recognized as potential therapeutic target various cancer; strategies used by Met-targeted agents summarized review.
mdpi.com
nagasaki-u.ac.jp
core.ac.uk 参考文章(85)
Timothy L. Ratliff, Robin T. Vollmer, Peter A. Humphrey, Xiaopei Zhu, Mark L. Day, Paul E. Swanson, Reza Zarnegar, Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. American Journal of Pathology. ,vol. 147, pp. 386- 396 ,(1995)
I. Lubensky, H. Neumann, Zhengping Zhuang, L. Schmidt, K. Junker, G. Glenn, M. Jeffers, W. M. Linehan, G. Vande Woude, G. Weirich, M. Walther, B. Zbar, P. Choyke, Two North American Families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene Cancer Research. ,vol. 58, pp. 1719- 1722 ,(1998)
Beatrice S. Knudsen, Magnus Edlund, Prostate cancer and the met hepatocyte growth factor receptor. Advances in Cancer Research. ,vol. 91, pp. 31- 67 ,(2004) , 10.1016/S0065-230X(04)91002-0
Mike Bradburn, Tim O'Brien, Sue Fuggle, Jeremy P. Crew, Roy Bicknell, David Cranston, Adrian L. Harris, Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Research. ,vol. 57, pp. 5281- 5285 ,(1997)
Hong-Lin Cheng, Barry Trink, Tzong-Shin Tzai, Hsiao-Sheng Liu, Shih-Huang Chan, Chung-Liang Ho, David Sidransky, Nan-Haw Chow, Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation Journal of Clinical Oncology. ,vol. 20, pp. 1544- 1550 ,(2002) , 10.1200/JCO.20.6.1544
Allard, Bernard, Fradet, TEtu, The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index BJUI. ,vol. 81, pp. 692- 698 ,(1998) , 10.1046/J.1464-410X.1998.00628.X
Piera Maggiora, Annalisa Lorenzato, Stefano Fracchioli, Barbara Costa, Massimo Castagnaro, Riccardo Arisio, Dionyssios Katsaros, Marco Massobrio, Paolo M Comoglio, Maria Flavia Di Renzo, The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Experimental Cell Research. ,vol. 288, pp. 382- 389 ,(2003) , 10.1016/S0014-4827(03)00250-7
H-L Cheng, H-S Liu, Y-J Lin, H H-W Chen, P-Y Hsu, T-Y Chang, C-L Ho, T-S Tzai, N-H Chow, Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder British Journal of Cancer. ,vol. 92, pp. 1906- 1914 ,(2005) , 10.1038/SJ.BJC.6602593
D. S. Grant, H. K. Kleinman, I. D. Goldberg, M. M. Bhargava, B. J. Nickoloff, J. L. Kinsella, P. Polverini, E. M. Rosen, Scatter factor induces blood vessel formation in vivo. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 90, pp. 1937- 1941 ,(1993) , 10.1073/PNAS.90.5.1937
A. Joseph, G. H. Weiss, L. Jin, A. Fuchs, S. Chowdhury, P. O'Shaugnessy, I. D. Goldberg, E. M. Rosen, Expression of Scatter Factor in Human Bladder Carcinoma Journal of the National Cancer Institute. ,vol. 87, pp. 372- 377 ,(1995) , 10.1093/JNCI/87.5.372